Gastroenterology
Volume 135, Issue 6 , Page 2156 , December 2008

Rosiglitazone for Nonalcoholic Steatohepatitis

  • Teoman Dogru

      Affiliations

    • Department of Gastroenterology, Gulhane Medical School, Etlik, Ankara, Turkey
    • ,
  • Cemal Nuri Ercin

      Affiliations

    • Department of Gastroenterology, Gulhane Medical School, Etlik, Ankara, Turkey
    • ,
  • Gokhan Erdem

      Affiliations

    • Department of Internal Medicine, Gulhane Medical School, Etlik, Ankara, Turkey
    • ,
  • Serkan Tapan

      Affiliations

    • Department of Biochemistry, Gulhane Medical School, Etlik, Ankara, Turkey
    • ,
  • Ilker Tasci

      Affiliations

    • Department of Internal Medicine, Gulhane Medical School, Etlik, Ankara, Turkey
    • ,
  • Alper Sonmez

      Affiliations

    • Department of Endocrinology, Gulhane Medical School, Etlik, Ankara, Turkey

References 

  1. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100–110
  2. Lorenzo C, Williams K, Hunt KJ, et al. The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30:8–13
  3. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  4. Dogru T, Sonmez A, Tasci I, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76:24–29
  5. Otsuka F, Sugiyama S, Kojima S, et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. Circ J. 2007;71:1703–1709
  6. Sung SH, Chuang SY, Sheu WH, et al. Adiponectin, but not leptin or high-sensitivity C-reactive protein, is associated with blood pressure independently of general and abdominal adiposity. Hypertens Res. 2008;31:633–640
  7. Tasci I, Dogru T, Naharci I, et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes. 2007;115:428–432
  8. Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton). 2007;12:147–153
  9. Riera-Guardia N, Rothenbacher D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab. 2008;10:367–375
  10. Erdem G, Dogru T, Tasci I, et al. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;82:214–218

 The authors disclose no conflicts.

PII: S0016-5085(08)01852-0

doi: 10.1053/j.gastro.2008.08.059

Gastroenterology
Volume 135, Issue 6 , Page 2156 , December 2008

Article Tools